×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Interview: How Cipla plans to bounce back after a weak Q2
Revenue is a challenge for us; little concerned about revenue growth: Cipla
See limited competition for Pulmicort; expect 3-4 more approvals by FY18-end: Cipla
Will continue to pursue inorganic growth in India & US: Torrent Pharma
New draft pharma policy will reduce risks like generalisation of mkt: JM Financial
Cipla to remain unfazed by Trump's protectionist policy
Looking for bigger partnership with Cipla: Serum Institute
Indian pharma cos need to step-up safeguards at plants: Handa
20% of Cipla FY17 revenues to come from US: Chirag Talati
Cipla completes acquisition of US cos InvaGen and Exelan
Sub-license for Hepatitis C drug beneficial for patients: Cipla
Cipla to pay for InvaGen, Exelan mostly through own funds
Aiming to achieve 70-80% organic growth: Cipla
Consumer health mkt growing at high double digit: Cipla
See Rs 400cr increase in top line over next few yrs: Hetero
What a potential Cipla-Serum merger could mean
Serum Institute in 'initial talks' to explore Cipla merger
Sun's margins may reduce to 30-32% post merger: Surajit Pal
Discussing partnerships, have done in-licensing deals:Cipla
Aiming growth of USD 3-4 bn by 2020: Cipla
Indian mkt needs hostile takeovers: Grant Thornton
Cipla mgmt rejig: Time to act as godfather says YK Hamied
Cipla eyes South Africa with plans for Cipla Medpro stake
Cipla launches anti-malarial drug in India
Cipla aims for 8-10% revenues this yr; Eyes overseas growth
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio